Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Profit After Tax: 2014-2024

Historic Profit After Tax for Ultragenyx Pharmaceutical (RARE) over the last 11 years, with Dec 2024 value amounting to -$569.2 million.

  • Ultragenyx Pharmaceutical's Profit After Tax fell 35.12% to -$180.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$579.8 million, marking a year-over-year decrease of 3.73%. This contributed to the annual value of -$569.2 million for FY2024, which is 6.17% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Profit After Tax stood at -$569.2 million for FY2024, which was up 6.17% from -$606.6 million recorded in FY2023.
  • In the past 5 years, Ultragenyx Pharmaceutical's Profit After Tax registered a high of -$186.6 million during FY2020, and its lowest value of -$707.4 million during FY2022.
  • For the 3-year period, Ultragenyx Pharmaceutical's Profit After Tax averaged around -$627.7 million, with its median value being -$606.6 million (2023).
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Profit After Tax surged by 53.67% in 2020 and then plummeted by 143.36% in 2021.
  • Yearly analysis of 5 years shows Ultragenyx Pharmaceutical's Profit After Tax stood at -$186.6 million in 2020, then crashed by 143.36% to -$454.0 million in 2021, then tumbled by 55.81% to -$707.4 million in 2022, then grew by 14.25% to -$606.6 million in 2023, then rose by 6.17% to -$569.2 million in 2024.